We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
CEVEC Pharmaceuticals has announced the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community.

Life Technologies will pay CEVEC a signing fee and various milestone payments and royalties on sales of the future products. Further details of the agreement were not disclosed. CEVEC will continue to expand its global license business of the CAP® and CAP-T® technologies for commercial use and industrial development purposes.

CEVEC’s transient CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns.

Life Technologies combines CEVEC’s proprietary protein expression system based on CAP cells with its tailored protein expression product portfolio (media, transfection reagents etc.) to enable research scientists worldwide to achieve highest yield and quality protein expression.

“We strongly believe in the tremendous value of the co-operation as the global research community is offered a fully optimized human expression system to transiently express proteins with superior yields and authentic human glycosylation patterns,” said Wolfgang Kintzel, CEVEC’s Chief Commercial Officer and Managing Director.

“We are extremely proud that Life Technologies has chosen the CAP technology to extend its top notch protein expression product portfolio,” added Dr. Rainer Lichtenberger, CEO of CEVEC.

According to CEVEC, the immortalized CAP cells are derived from primary human amniocytes and meet highest ethical standards. CAP cells are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors and can be efficiently transfected with commercially available transfection reagents.
Advertisement